Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 01, 2025 01:00 ET | Source: Pharming Group N.V.

Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years

Pharming sNDA for leniolisib in children aged 4-11 years with APDS accepted and granted Priority Review by FDA.